Table 2.

Use of reperfusion therapy, heparin, and oral anticoagulants in the acute management of ACS according to estimated CrC

Medication Use≤45 ml/min (n = 152)45 to 60 ml/min (n = 198)>60 ml/min (n = 728)Differencea,c
Thrombolysis or primary PTCR in candidates by ECG criteriab (%)22 (69)52 (83)182 (77)−8 (−24, 8)
    tertiary care centers16 (84)41 (85)142 (80)4 (−13, 21)
    community-based centers6 (46)11 (73)40 (68)−22 (−52, 8)
Heparin use—acute treatment of ACS (%)138 (91)171 (86)663 (91)0 (−5, 5)
Heparin use or already receiving warfarin—acute treatment of ACS (%)143 (94)172 (87)664 (91)3 (−1, 7)
  • a Reported differences are between subjects with a CrC ≤45 ml/min and the reference group (>60 ml/min) and are expressed in percent with a 95% CI.

  • b There were 330 subjects considered appropriate candidates for reperfusion therapy by ECG criteria (≥1-mm ST-segment elevation in two leads): 32 with a CrC ≤45 ml/min, 63 in the 45- to 60-ml/min category, and 235 with a CrC >60 ml/min.

  • c There were no significant between-group differences by χ2.